Medicines are an essential component of healthcare, but they do not always reach the patient. High medicine prices and the increasing problem of shortages are major contributing factors. On top, there is little commercial interest from the pharmaceutical industry to find new treatments for certain diseases, and new medicines do not always represent a therapeutic advance.

The EU institutions must make the most of the ongoing revision of the pharmaceutical legislation and ensure it leads to better and more equitable access to medicines across Member States.